Press Releases

Latest

AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi
22 August 2019
Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer
21 August 2019
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
20 August 2019
Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer
14 August 2019
Calquence granted US Breakthrough Therapy Designation for chronic lymphocytic leukaemia
14 August 2019
Tagrisso significantly improves overall survival in the Phase III FLAURA trial for 1st-line EGFR-mutated non-small cell lung cancer
9 August 2019
Lynparza Phase III PROfound trial in HRR* mutation-selected metastatic castration-resistant prostate cancer met primary endpoint
7 August 2019
Forxiga label updated in the EU in type-2 diabetes
5 August 2019
H1 2019 Results
25 July 2019
Update on US regulatory decision for Farxiga in type-1 diabetes
15 July 2019

Can't find what you are looking for? Our Press Release archive contains all of our press releases dated before 2018 so you should be able to find just what you are looking for.

Explore archive

Contact us

Gonzalo Viña

Head of Global Media Relations

+44 203 749 5916

Rob Skelding

Director Global Media Relations

+44 203 749 5821

Matthew Kent

Director Global Media Relations

+44 203 749 5906

Rebecca Einhorn

Director Global Media Relations

+1 301 398 1802

Jennifer Hursit

Manager Global Media Relations

+442037495762

Christina Malmberg Hägerstrand

Media Relations Director, Sweden and Nordic-Baltic

+46 8 552 53 106

Lotta Sjösten

Manager Media Relations, Sweden

+46 8 553 271 10

US Media Team

+1 302 885 2677

Press Releases

Contact us

Subscribe

Follow us

LinkedIn